header logo image


Page 38«..1020..37383940..50..»

Archive for the ‘Cell Therapy’ Category

Alan Fine on Advances in stem cell therapy – Video

Monday, December 10th, 2012


Alan Fine on Advances in stem cell therapy
Alan Fine, Professor of Medicine, Director Stem Cell Biology Program, Boston University Alan Fine spoke at the Expert Exchange Roundtable on Pushing the boundaries of longevity, 9 September 2011, sSwissnex Boston, Cambridge, Massachusetts, USAFrom:swissretvViews:12 0ratingsTime:01:18:35More inEducation

The rest is here:
Alan Fine on Advances in stem cell therapy - Video

Read More...

Stem Cell Therapy (IMC) – Video

Monday, December 10th, 2012


Stem Cell Therapy (IMC)
New Project 40From:OmarGonzalezMDViews:0 0ratingsTime:01:48More inScience Technology

Here is the original post:
Stem Cell Therapy (IMC) - Video

Read More...

MissouriCuresEvents_Oct2012_Dr.MarieCsete – Video

Monday, December 10th, 2012


MissouriCuresEvents_Oct2012_Dr.MarieCsete
"The stem cell therapy race: roadblocks to the finish line", as presented by Dr. Marie Csete at The Danforth Center on behalf of Missouri Cures Education Foundation #39;s Speaker Series in October, 2012.From:MissouriCuresEventsViews:1 0ratingsTime:51:36More inNonprofits Activism

More here:
MissouriCuresEvents_Oct2012_Dr.MarieCsete - Video

Read More...

Sources Of Stem Cells | Stem Cell Malaysia – Video

Monday, December 10th, 2012


Sources Of Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Sources of stem cells play a critical role in determining the outcome of stem cell therapy. Without a clear idea of the sources of stem cells, it is risky to be engaged in any form of stem cells treatment. The sources of stem cells include the type of animals, the location of the animals, and the parts of the animal. For more information on sources of stem cells, please visit Stem Cell Malaysia at stemcellmalaysia.comFrom:stemcells2012Views:207 9ratingsTime:04:13More inScience Technology

See the original post here:
Sources Of Stem Cells | Stem Cell Malaysia - Video

Read More...

Robert Toves Testimonial (Parkinson’s Disease) Stem Cell Therapy – Video

Monday, December 10th, 2012


Robert Toves Testimonial (Parkinson #39;s Disease) Stem Cell Therapy
Robert Toves is a patient at Integra Medical Center, Mr.Toves suffers of Parkinson #39;s disease and has come to try Dr.Gonzalez method of stem cell therapy, just less than an hour after the stem cell therapy great results seem to show.From:OmarGonzalezMDViews:1 0ratingsTime:05:58More inScience Technology

Original post:
Robert Toves Testimonial (Parkinson's Disease) Stem Cell Therapy - Video

Read More...

Stem Cell Therapy (Cerebral Palsy) – Video

Monday, December 10th, 2012


Stem Cell Therapy (Cerebral Palsy)
New Project 43From:OmarGonzalezMDViews:0 0ratingsTime:02:07More inScience Technology

See the article here:
Stem Cell Therapy (Cerebral Palsy) - Video

Read More...

Making Stem Cell Thearpy Safer – Mayo Clinic – Video

Wednesday, December 5th, 2012


Making Stem Cell Thearpy Safer - Mayo Clinic
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells. Study Author, Dr. Timothy Nelson provides and overview.From:mayoclinicViews:45 0ratingsTime:02:04More inScience Technology

Continue reading here:
Making Stem Cell Thearpy Safer - Mayo Clinic - Video

Read More...

Precision StemCell’s Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

Wednesday, December 5th, 2012

GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.

The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.

"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."

In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said

The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.

The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.

In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."

About Precision StemCell

Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.

Contact:

More here:
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

Read More...

.Rejuvenare Stem Cell Therapy 888-988-5456 – Video

Monday, December 3rd, 2012


.Rejuvenare Stem Cell Therapy 888-988-5456
Rejuvenare Autologous Adult Stem Cell Therapy welcome video asks and answers questions on whether someone is a candidate for stem cell therapy. More can be found at http://www.rejuvenare.comFrom:rejuvenareViews:2 0ratingsTime:01:01More inPeople Blogs

See the article here:
.Rejuvenare Stem Cell Therapy 888-988-5456 - Video

Read More...

NeoStem to Present at Multiple Conferences in December

Monday, December 3rd, 2012

NEW YORK, Dec. 3, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in December.

World Stem Cell Summit

RedChip Small-Cap Equities Virtual Conference

Cell Therapy Manufacturing (Informa Life Sciences' 3rd Annual VIC Congress 2012)

American Society of Hematology Annual Meeting and Exposition ("ASH")

NeoStem's abstract on VSELTM Technology titled "A Lin-CD45-CD34+ Population of Extracellular Vesicles in Human Blood That Mimics Very Small Embryonic-Like Stem Cells (VSELs) by Flow Cytometry" has been selected for publication online in December in conjunction with the ASH Annual Meeting and Exposition, December 8-11, 2012. The abstract will be available at http://bloodjournal.hematologylibrary.org/site/misc/ASH_Meeting_Abstracts_Info.xhtml.

About NeoStem, Inc.

NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert to create a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we are well positioned to succeed.

For more information, please visit http://www.neostem.com.

Excerpt from:
NeoStem to Present at Multiple Conferences in December

Read More...

QualityStocks News – International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages …

Saturday, December 1st, 2012

Company's ability to do something nobody has done before confirms world-leader status.

Scottsdale, AZ (PRWEB) November 30, 2012

In the companys news yesterday,

International Stem Cell Corp. has achieved a critical milestone towards the clinical development of its non-embryonic stem cell therapy.

Through much dedication and hard work, the companys research and development team has created the worlds first human clinical-grade stem cell lines that can be immune-match to millions of individuals. ISCOs existing research-grade parthenogenetic stem cell lines, one of which may be an immune-match to approximately 70 million people, are being used in pre-clinical development. ISCO is now in a position to conduct clinical trials in the United States.

Weve been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and Im excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. Im optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide, stated Dr. Semechkin, CEO and Co-Chairman of the Board.

Created using ISCOs proprietary technology, the new stem cell lines represent the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is necessary to conduct clinical development programs.

Independent third-party testing has confirmed the new lines to be homozygous in the HLA coding regions. This means that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection; a distinct clinical advantage over embryonic stem cells. The company anticipates the new lines to immune-match millions of individuals. They will be added to ISCOs existing bank and provide a platform from which to develop cells and tissue for clinical use.

The importance of this breakthrough cannot be overstated, emphasized Dr. Craw, Executive Vice President of ISCO. Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company.

About QualityStocks

Originally posted here:
QualityStocks News - International Stem Cell Corp. Advances Groundbreaking Stem Cell Therapy with Distinct Advantages ...

Read More...

Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

Saturday, December 1st, 2012

Autologous Cell Therapy Market reserach report gives a detailed analysis about state of the art of both autologous stem cell and non-stem cell treatments. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally.

(PRWEB) November 30, 2012

Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy (ACT) Market (2012 - 2017).

http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html

Early buyers will receive 10% customization on reports.

There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected to revolutionize the area of bio-pharma and personalized medicine. High incidence and lack of effective treatment for several diseases will drive the ACT technology in developed and developing nations.

Investment activities, for past five years are actively held in research and developments, attracting interests of cell therapy industry firms, medical centers and academic institutions. ACT potential can be demonstrated by mergers, collaborations, acquisitions and partnerships that happened actively between the ACT technology developing companies in past three years. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

See the original post here:
Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

Read More...

SCMOM 2012_NeoStem – Video

Thursday, November 29th, 2012


SCMOM 2012_NeoStem
NeoStem, Inc. is an emerging technology leader in the fast-developing cell therapy market. Its business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC, with a medically important cell therapy product development program. NeoStem #39;s most clinically advanced therapeutic, AMR-001, is being developed at its Amorcyte subsidiary, which is enrolling patients in a Phase 2 trial for preservation of heart function after a heart attack. Athelos Corporation, also a NeoStem subsidiary, is in early stage clinical exploration of a T-cell therapy for autoimmune conditions. Pre-clinical assets include our VSELTM Technology platform and our mesenchymal stem cell product candidate for regenerative medicine. http://www.neostem.com Presenter: Jonathan Sackner-Bernstein, NeoStem, Inc.From:AllianceRegenMedViews:4 1ratingsTime:14:54More inScience Technology

Excerpt from:
SCMOM 2012_NeoStem - Video

Read More...

SCMOM 2012_Stanford Cardiovascular Institute – Video

Thursday, November 29th, 2012


SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology

Read more here:
SCMOM 2012_Stanford Cardiovascular Institute - Video

Read More...

SCMOM 2012_Regen BioPharma, Inc. – Video

Thursday, November 29th, 2012


SCMOM 2012_Regen BioPharma, Inc.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials). The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 18 - 24 months grows technologies from laboratory to an asset ready for spin-off or sale to feed the pipeline of Big Pharma. http://www.regenbiopharma.com Presenter: J. Christopher Mizer, President, Regen BioPharma, Inc.From:AllianceRegenMedViews:4 1ratingsTime:09:13More inScience Technology

Link:
SCMOM 2012_Regen BioPharma, Inc. - Video

Read More...

Different organ-derived stem cell injections improve heart function in rats

Thursday, November 29th, 2012

Washington, November 28 (ANI): When mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy, a study has found.

The study, carried out by researchers at Oslo University Hospital and the Norwegian Center for Stem cell Research, Oslo University, sought to determine if MSCs from different organs would result in different functional outcomes.

"Despite advances in revascularization and medical therapy, acute myocardial infarction (AMI) and heart failure are still important causes of morbidity and mortality in industrialized countries," said study co-author Dr. Jan E. Brinchmann of the Norwegian center for Stem Cell Research at Oslo University Hospital, Oslo.

"AMI leads to a permanent loss of contractile elements in the heart and the formation of fibrous scarring. Regeneration of contractile myocardium has been a target of cell therapy for more than a decade," he added.

According to Dr. Brinchmann, MSCs tolerate hypoxia, secrete angiogenic factors and have been shown to improve vascularization; thus, they have properties suggesting that they may beneficially impact AMI, chronic heart failure and angina pectoris after cell transplantation.

Following injection into the "border zone" and infarct area of immunodeficient rats one week after induced myocardial infarction, the researchers used echocardiography to measure myocardial function and other analyses to measure the size of scaring, density of blood vessels in the scar, and the health of myocardial tissues.

"Our results showed that intramyocardial injection of both ADSCs and SM-MSCs one week after AMI led to a substantial decrease in infarct size and a significant improvement in left ventricle function when compared with injections of cell culture medium alone," concluded the researchers.

"There was a trend toward better functional improvement in the SM-MSC group when compared to the ADSC group, but this did not reach significance," they added.

They concluded that many questions remain unanswered, including the question of whether MSCs isolated from different organisms could result in different functional outcomes.

Other unanswered questions relate to the optimal time delay between the onset of myocardial infarction and injection of MSCs. These cells do, however, still appear to be "a potentially interesting adjuvant treatment modality for selected patients following acute myocardial infarction," they concluded.

Read more from the original source:
Different organ-derived stem cell injections improve heart function in rats

Read More...

Stemlogix Reports Idaho Veterinarians Perform First in U.S. Combination Regenerative Medicine Treatment on Injured Horse

Thursday, November 29th, 2012

Procedure Combines Point-of-Care Stem Cell Therapy and Enriched Mesenchymal Stem Cell Injection

NAMPA, ID--(Marketwire - Nov 29, 2012) - Veterinarians from Idaho Equine Hospital, including Dr. William Maupin and Dr. Stuart Shoemaker, performed the first-ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

This injury can be challenging for veterinarians to successfully treat and return the horse to athletic competition.

The veterinary team and the scientific team at Stemlogix, LLC determined that the best treatment protocol would be to treat him with point-of-care stem cell therapy using the Stemlogix In-Clinic Regenerative Medicine System and then perform a follow up treatment a few weeks later using culture expanded mesenchymal stem cells. He received a dose of the point-of-care stem cell therapy three weeks ago and three weeks later received an injection of culture expanded mesenchymal stem cells.

Stemlogix, LLC pioneered the landmark stem cell therapy treatment regimen and this is the first time this combination stem cell therapy treatment has ever been performed on a horse. The team that treated the horse believes this revolutionary treatment protocol will give him the best chance for an improved quality of life and provides the best opportunity for restoring the injured tissue back to its normal structure instead of healing with scar tissue.

"Due to the severity of the injury and the poor circulation present in the sesamoidean ligament we elected to perform a two-step therapeutic approach," said Dr. Maupin. "We first injected adipose derived stem cell therapy produced patient-side to initiate an environment of healing.

"In addition, we injected culture expanded mesenchymal stem cells. This secondary expanded and enriched mesenchymal stem cell therapy treatment may further restore normal tissue structure or actual ligament tissue."

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the Stemlogix state-of-the-art cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

The Stemlogix In-Clinic Regenerative Medicine System rapidly produces a composition of stem cells at the point-of-care containing an abundance of mesenchymal stem cells, endothelial progenitor cells, among other cell types. This assortment of stem cells provides additional growth factors and therapeutic proteins to stimulate healing. This system offers veterinarians an optimal treatment tool that is convenient and effective in treating debilitating equine diseases and injuries.

On the other hand, the culture expanded stem cell therapy contains a high number of purified mesenchymal stem cells which makes this therapy better suited for treating specific indications such as orthopedic injuries, autoimmune diseases and other degenerative diseases. Mesenchymal stem cells are multi-potent or have the ability to form into a variety of new tissues such as bone, cartilage, ligaments, and tendons.

See the original post:
Stemlogix Reports Idaho Veterinarians Perform First in U.S. Combination Regenerative Medicine Treatment on Injured Horse

Read More...

International Stem Cell Corporation Announces Significant Progress Towards Clinical Development

Thursday, November 29th, 2012

CARLSBAD, CA--(Marketwire - Nov 29, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on the development of therapeutic products, today announced the achievement of a critical milestone towards the clinical development of its stem cell therapy.

The Company's research and development team has created the world's first human clinical-grade stem cell lines with the ability to immune-match millions of individuals. ISCO's existing research-grade parthenogenetic stem cell lines, one of which contains the most common immune type in the Caucasian population and may be an immune-match to approximately 70 million people, are used in pre-clinical development. These new clinical-grade stem cell lines position ISCO to be able to conduct clinical trials in the United States.

Dr. Semechkin, CEO and Co-Chairman of the Board, comments, "We've been working diligently for three years to perfect this technology, which was first developed by our scientific founder, Dr. Elena Revazova in Moscow, and I'm excited to report that we have been able to derive new stem cell lines in the United States under the US and California regulatory frameworks. I'm optimistic that the new parthenogenetic stem cell lines, by providing a potentially unlimited supply of cells and tissue for transplantation, will be of great benefit to the medical community and patients world-wide."

The new stem cell lines, created using ISCO's proprietary technology, are the first of a new generation of clinical-grade human parthenogenetic stem cell (hpSC) lines created in the United States under US regulatory oversight and designed to meet FDA regulations. The US Food and Drug Administration developed Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards to ensure the safety of products developed for clinical use. Conforming to GMP is extremely important as it means that the cells can be used in clinical development programs.

The new lines have been confirmed by independent third-party testing to be "homozygous" in the HLA coding regions meaning that they have a simple genetic profile in the critical areas of the DNA that code for immune rejection. This feature is one of the most important differences of hpSC when compared with embryonic stem cells and a distinct clinical advantage because of their ability to be immune-matched to the patient. We expect the new lines to immune-match millions of individuals, and will be added to ISCO's existing bank providing a platform from which to develop cells and tissue for clinical use.

"The importance of this breakthrough cannot be overstated," commented Dr. Craw, Executive Vice President of ISCO. "Expanding our collection is not only important for our therapeutic programs, but also further establishes our leadership position in human stem cell technology. Achieving this critical milestone moves us along the path to make the transition into a clinical stage company."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Original post:
International Stem Cell Corporation Announces Significant Progress Towards Clinical Development

Read More...

Professors Critique Stem Cell Medical Tourism

Thursday, November 29th, 2012

A panel at the Harvard Law School Wednesday discussed the ethical debate over the use of embryonic stem cells in the United States, focusing on the burgeoning controversy surrounding the role of stem cell therapy in medical tourism.

Medical tourism, in which patients travel internationally to gain access to specific health care services, has become increasingly common, panelists said. They said that reasons for medical tourism range from basic hip replacement surgery to black market organ sales. As most stem cell therapies are not approved in the United States, numerous patients are going abroad to countries like China and Russia where treatment is legal.

Panelist I. Glenn Cohen, an assistant professor at the Law School, said that it was probable that a Chinese stem cell facility performs several hundred thousand of these treatments yearly. He said that numerous celebrities, including football quarterback Peyton Manning, have reportedly traveled abroad to receive stem cell treatment not approved by the FDA.

A number of facilities claim to use stem cells to cure a wide array of diseases. University of Alberta law professor Timothy Caulfield, another panelist, pointed out that a simple Google search leads potential patients to a plethora of websites which claim that diseases such as autism and cancer can be cured through stem cell therapy.

Its being offered as routine, its being offered as safe, its being offered as effective, Caulfield said, citing his own 2008 study on the subject, Of course, none of them being offered matched what the scientific literature said.

According to American history professor Jill Lepore, the hyper-acceleration of enthusiasm for stem cell therapy is reminiscent of a century ago when science journalism and government funding for science research began to blossom. Lepore pointed out how public excitement over scientific procedures has affected society in the past, popularizing cryonics research and the work of Eugene Steinach, who claimed his vasectomy operation reversed the aging process.

Panelists said that one issue with stem cell tourism is the number of health risks associated with such procedures, citing a number of instances where stem cell therapy caused serious harm.

They also noted that public discussion about stem cell therapy has been markedly positive, lending an air of legitimacy to stem cell therapy that hasnt been validated by research.

Articles criticizing stem cell tourism, on the other hand, have generally received a less favorable response. Caulfield told the audience that when he co-wrote an article in The Atlantic criticizing stem cell therapy, he was accused as being a nutball Canadian socialist bioethicist.

The panelists emphasized that more accurate information should be provided to the public regarding stem cell treatments.

Continued here:
Professors Critique Stem Cell Medical Tourism

Read More...

Two Delhi centres ready to try stem cell therapy on paraplegics

Tuesday, November 27th, 2012

Ahead of a planned five-centre nationwide trial, the Indian Council of Medical Research (ICMR) has approved a special project at the AIIMS Trauma Centre in New Delhi where stem cell therapy will be conducted on complete paraplegics and quadriplegics to try and revive limb function.

A similar trial will be conducted at the Indian Spinal Injuries Centre (ISIC) in Vasant Kunj, south-west Delhi where 21 patients have already been registered. This project too has been approved by the ICMR.

Senior ICMR scientists from the apex committee to monitor stem cell research said the five-centre trial will be coordinated from ISIC and is in the final stages of approval.

This will be the first national ICMR trial of autologous bone marrow stem cell transplant on complete quadriplegics and paraplegics. We are finalising the number of patients. The ISIC will be the coordinating centre. The next meeting has been scheduled for December 4, a senior scientist said.

An autologous stem cell transplantation is a procedure in which stem cells are removed, stored and returned to the same person.

For its project, the AIIMS Trauma Centre has registered eight patients. They will be injected with stem cells from their own bone marrow to see if the damaged neurological function can be regenerated. Doctors have cautioned that earlier trials on incomplete quadriplegics and paraplegics have not suggested significant clinical improvement.

Dr Deepak Aggarwal, associate professor of neurosurgery at the AIIMS Trauma Centre who is coordinating the study, said: We have necessary clearances from our internal ethics committee and the national apex committee for stem cell research and therapy which has members from the ICMR and Department of Biotechnology.

... contd.

Link:
Two Delhi centres ready to try stem cell therapy on paraplegics

Read More...

Page 38«..1020..37383940..50..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick